BOLDHealthcare · BiotechnologyBOLD Stock Forecast: Boundless Bio, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Boundless Bio, Inc. hold a median 12-month price target of $4 — +33.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
BOLD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Boundless Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Value (19): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BOLD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BOLD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +33.3% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.00 |
| 2 June 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 28 May 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 13 Dec 2024 | Guggenheim | Downgrade | Neutral | — |
| 22 Apr 2024 | Guggenheim | Initiates | Buy | — |
| 22 Apr 2024 | Leerink Partners | Initiates | Outperform | — |
| 22 Apr 2024 | Piper Sandler | Initiates | Overweight | — |
| 9 Dec 2019 | Evercore ISI Group | Downgrade | In-Line | — |
| 6 Dec 2019 | JP Morgan | Downgrade | Neutral | — |
| 4 Dec 2019 | Chardan Capital | Downgrade | Neutral | $60 |
| 4 Dec 2019 | SVB Leerink | Downgrade | Market Perform | — |
| 3 Dec 2019 | Baird | Upgrade | Neutral | — |
| 3 Dec 2019 | BMO Capital | Downgrade | Market Perform | $47 → $60 |
| 3 Dec 2019 | Citigroup | Upgrade | Neutral | $30 → $60 |
| 3 Dec 2019 | Guggenheim | Downgrade | Neutral | — |
| 3 Dec 2019 | HC Wainwright & Co. | Downgrade | Neutral | $60 |
| 3 Dec 2019 | Piper Jaffray | Downgrade | Neutral | — |
| 3 Dec 2019 | Piper Sandler | Downgrade | Neutral | $55 → $60 |
| 3 Dec 2019 | Raymond James | Downgrade | Market Perform | — |
| 3 Dec 2019 | Wedbush | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BOLD appears on the weeks it earns a place.
BOLD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Boundless Bio, Inc. (BOLD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.2×
- Price / sales
- —
- Price / book
- 1.0×
- EV / EBITDA
- 0.1×
Cheaper than 73% of US stocks
Cheaper than 73% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −67.9%
- Return on assets
- −32.8%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BOLD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Boundless Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BOLD stock
What is the BOLD stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Boundless Bio, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BOLD stock a buy right now?
Of the 1 analysts covering Boundless Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boundless Bio, Inc. 74 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BOLD?
As at 22 Aug 2026, Boundless Bio, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
Will BOLD stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +33.3% from the last close, and Ticker Nerd's factor model ranks Boundless Bio, Inc. 74 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BOLD stock forecast for 2030?
No analyst covering Boundless Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BOLD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has BOLD stock performed over the past year?
Boundless Bio, Inc. returned +163.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Boundless Bio, Inc. do?
Boundless Bio Inc. is a biotechnology company at the forefront of developing novel therapies for oncogenic amplification in cancer treatment.
About Boundless Bio, Inc.
Boundless Bio Inc. is a biotechnology company at the forefront of developing novel therapies for oncogenic amplification in cancer treatment. The primary focus of the company is on the creation of precision medicines that target extrachromosomal DNA (ecDNA), which plays a crucial role in cancer progression and resistance to existing therapies. By pioneering research in this area, Boundless Bio aims to address significant unmet needs in oncogenic amplification-driven cancers, opening pathways for more effective treatment regimens. Boundless Bio operates in the life sciences sector, specifically impacting areas related to genetic research and cancer therapeutics. Its innovations are not only driving forward the understanding of cancer biology but are also crucial in developing targeted solutions that could significantly improve patient outcomes. With its groundbreaking approach, Boundless Bio holds a strategic position in the biotechnology market, contributing to the advancement of precision medicine. The company's work underscores a vital shift towards more personalized cancer treatments, highlighting the potential impact of genomic research in transforming healthcare and offering hope to patients with limited treatment options.
CEO Mr. Zachary D. Hornby · 28 employees · United States · https://boundlessbio.com